Heat Biologics COVID-19 vaccine induces expansion of both “killer” CD8 + T-cells that kill infected cells, as well as CD4 + T cells that “aid” production support. highly specific antibodies. Both T-cell subsets have been shown to release cytokines that amplify the antiviral immune response, and during vaccination, the CD8 + T cells in memory travel to the lungs and airways – the site Specific tissue is of interest for SARS-CoV-2 infection. CD8 + T T cells reside in the lung tissue and these airways play an important role in inducing an effective response to the respiratory virus.
Natasa Strbo, MD, DSc, Assistant Professor of Microbiology and Immunology at Miami Miller University School of Medicine and co-developer of Heat’s gp96 platform commented, “We are highly encouraged by the generated animal data. Out around the COVID-19 vaccine and we look forward to releasing full details of this study in the coming weeks. Specifically, we have already documented a number of important immune responses due to the vaccine against again SARS-CoV-2 produced after one injection, consisting of CD8 + specific SARS-CoV-2 and CD4 + T cells in the lungs and airways. “
Jeff Wolf, CEO of Heat Biologics, commented, “We are encouraged by the advances being made by other companies that are developing vaccines against COVID-19. Most of these approaches are primarily promoting antibody responses, our COVID-19 vaccine is designed to boost T-cell primary immunity along with innate antibody and immunity. Therefore, we believe our vaccine has the potential to be used as a stand-alone vaccine or in combination with other approaches to improve efficacy. by Dr. Strbo and her team at the University of Miami, as well as Heat’s team, who have been working around the clock because of the urgency of the pandemic. We look forward to providing more updates. as soon as possible. “
Heat Biologics is a biopharmaceutical company focused on developing first-class therapies to modulate the immune system. The company’s gp96 platform is designed to trigger immune responses against cancer or pathogenic antigens. The company has a number of developing gp96-based product candidates, including HS-110, which completed registration in trial phase 2, HS-130 in Phase 1, and the COVID- vaccine program. 19 in the pre-clinical development process. In addition, Heat is developing a proprietary immunomodulatory antibodies system, including PTX-35, which is currently in Phase 1 testing.
www.heatbio.comand also follow us on Twitter. “data-reacttid =” 24 “> For more information, please visit: www.heatbio.com and follow us on Twitter.
The story continues